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Bone morphogenetic protein-2 (BMP-2) is known to initiate the differentiation of 
mesenchymal stem cells (MSCs) into osteoblasts and chondrocytes in vivo and in vitro,[1] as 
well as the transdifferentiation of mouse myoblasts C2C12 cell line into mineralizing bone-
like cells.[2, 3] The BMP-2 signaling pathway is activated by the binding of the growth factor 
to two types of transmembrane serine/threonine kinase receptors, the BMP type I (BMPRI) 
and type II (BMPRII) receptors. Binding of BMP-2 to BMPRI and BMPRII induces the 
phosphorylation of the SMAD1/5/8 complex, which then together with co-SMAD (SMAD4) 
translocates to the nucleus and, with other DNA-binding proteins, participates in the 
transcriptional regulation of osteogenic target genes.[4] 
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The clinical use of BMP-2 was approved in 2002 by the Food and Drug Administration in the 
USA and validated by the national Medical Agencies in Europe. BMP-2 has been rapidly 
introduced into orthopedic clinical practice[5] but, in some cases, even high doses (up to 2 
mg/level) appear only marginally effective, likely due to an autocrine BMP-2 inhibition by 
noggin the major extracellular BMP antagonist, at sites of BMP-2 application.[6] Therefore, 
improving BMP-2 activity, by using delivery systems that suppress BMP-2 inhibition by 
noggin, would help in overcoming current challenges in BMP-2 clinical application.[7]  
The development of materials that are able to control BMP-2 molecular presentation and local 
concentration, is an essential approach for a deeper understanding of BMP-2 functions and the 
modulation of its biological activity.[8] 
In tissues, BMP-2 is bound to extracellular matrix (ECM) components such as proteins[9] and 
glycosaminoglycans (GAGs), in particular to heparan sulfate (HS)[10, 11]. BMP-2 is a 
homodimeric protein and has been reported to bind in vitro to heparin (Hp), a highly sulfated 
form of HS, via a binding site located at the N-terminus (Figure 1A) with an affinity of 
approximately 20 nM.[12] The binding of BMP-2 to HS, on the other hand, remains to be fully 
characterized in terms of stoichiometry, affinity and concomitant HS morphological changes. 
HS, a linear polysaccharide formed by variably sulfated repeating disaccharide units, is 
typically covalently attached to core-proteins forming HS proteoglycans (HSPGs). The 
functions of HSPGs depend on their structure and location, being either at the cell surface or 
as part of the ECM.[13] 
Contradictory effects of cell surface HSPGs on BMP-2 activity have been reported. On the 
one hand, endogenous HSPGs negatively modulate both chondrogenic[14] and osteogenic[10] 
differentiation by inhibiting the activation of BMP-2 signaling. On the other hand, HSPGs act 
as BMP-2 co-receptors, promoting the formation of complexes between BMPRII and BMPRI, 
thereby enhancing the bioactivity of BMP-2.[15] Interestingly, the BMP antagonist noggin also 
binds to HS.[16] Once bound to cell surface HSPGs, noggin maintains its function to inhibit 
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the activity of BMP-4, another member of the BMP family, by blocking the binding epitopes 
for BMPRI and BMPRII.[16, 17] 
To date, the role of HSPGs in the extracellular space (ECM-HSPGs) on BMP-2 bioactivity is 
only partially explored. The main functions so far attributed to ECM-HSPGs are to prevent 
the diffusion of growth factors away from the regions where they are likely to be required.[18] 
However, it is still unknown if these HSPGs can positively modulate BMP-2 biological 
activity thus enhancing in vitro osteogenic differentiation.[19]  
The presence of HS added to the culture media of BMP-responsive cells (C2C12 myoblasts) 
prolongs SMAD 1/5/8 phosphorylation in these cells and reduces the interactions with the 
antagonist noggin,[11, 20] in contrast to the effect of cell surface HSPGs.[16] Since in vivo HS is 
not in solution, but rather covalently bound to core-proteins through its reducing end forming 
HSPGs,[21] administering HS in the cell culture media is unlikely to be representative of the in 
vivo extracellular HS. 
Biomimetic platforms presenting HS in a bound and oriented manner are therefore suitable to 
explore (i) the characteristics of HS/BMP-2 binding at the molecular and cellular levels, (ii) 
the impact of BMP-2 presentation on BMP-2 activity, and (iii) the interaction of noggin with 
grafted HS and its recognition of the HS-bound BMP-2. The strength of such platforms lies in 
the precise molecular presentation, which gives the ability to control and characterize BMP-2 
interactions with HS, as well as the possibility to further exploit them as substrates for 
investigations on the impact of HS on BMP-2 activity in cells. We designed our model 
surfaces in a way that HS is grafted by its reducing end,[22] mimicking its attachment to HSPG 
core proteins in vivo. To this end, we functionalized the reducing end of HS with biotin and 
used gold-coated surfaces functionalized first with a mixed monolayer of oligoethyleneglycol 
(OEG)-thiol and biotin-OEG-thiol and then with a streptavidin monolayer as substrates[23] 
(Figure 1B). The OEG monolayer passivates against non-specific binding of proteins, here 
tested using bovine serum albumin (BSA) (Figure S1), whereas streptavidin (SAv) binds 
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through a specific interaction with the biotin end-groups and forms a rigid monolayer. Such 
monolayer serves then as a mediator for the immobilization of biotinylated compounds such 
as biotinylated HS (b-HS; Figure 1C) and biotinylated BMP-2 (b-BMP2; Figure 1D). BMP-
2 binds to SAv via a biotin-PEG12-NHS ester linker (of ~5.6 nm contour length) which reacts 
with primary amines of the growth factor. Surface functionalization steps, specificity of the 
molecular binding and mechanical properties of the biomolecular films were characterized by 
quartz crystal microbalance with dissipation monitoring (QCM-D); adsorption and desorption 
rates of the different biomolecules, as well as biomolecular surface densities, were quantified 
by spectroscopic ellipsometry (SE). 
Figure 1C and D shows QCM-D characterization of the two biomimetic platforms (f and 
D correspond to the fifth overtone). After the formation of a SAv monolayer with an 
expected thickness of approximately 4 nm [24] (determined using Sauerbrey’s equation; 
Figure 1C, 60 to 80 min), b-HS adsorbs rapidly forming a hydrated and soft film, indicated 
by the increase in dissipation of 4.5  0.5  10-6 (Figure 1C, 90 to 110 min). BMP-2, 
incubated at a concentration of 96 nM, stably binds to the b-HS film causing an increase in 
film rigidity, as demonstrated by the negative dissipation shift of -0.9  0.1  10-6 (Figure 1C, 
150 to 180 min). Complementary assays based on fluorescence recovery after photobleaching 
(FRAP), using films of b-HS grafted to supported lipid bilayers in the fluid phase, revealed 
that BMP-2 binding reduces the lateral mobility of HS chains substantially. This suggests that 
the increased rigidity arises from cross-linking of HS chains mediated by the growth factor 
(Figure S2). This phenomenon has been reported for other ECM signaling proteins, such as 
chemokines and growth factors, some of which present multiple HS binding sites.[26] We 
speculate that HS cross-linking induced by BMP-2 might be due to the presence of two or 
more independent Hp/HS binding sites at the N-terminus region of the BMP-2 dimer, as 
previously predicted.[25] A mutant form of BMP-2, EHBMP-2, where the N-terminal region 
responsible for the Hp binding was substituted by a heterologous sequence from human 
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interleukin-2,[12] does not bind to b-HS (Figure 1C, grey curve) and does not induce HS film 
cross-linking (Figure S2). This demonstrates that BMP-2 binds HS specifically through the 
same site as Hp.  
For comparison, we also adopted a second BMP-2 immobilization strategy that does not 
involve HS. In this case, biotinylated BMP-2 (b-BMP2) binds directly to the SAv monolayer 
until saturation (Figure 1D, 50 to 110 min). When incubated at the same concentration (96 
nM) without the biotin tag, BMP-2 does not bind stably (Figure 1D, gray curve) 
demonstrating the b-BMP2 is specifically attached via biotin to the SAv monolayer. 
To quantify the binding strength of BMP-2 to b-HS films, we used spectroscopic ellipsometry 
(SE) and performed a titration assay (Figure S3A). The titration curve (Figure S3B) was 
approximated well by the simple Langmuir isotherm:  
 , (1) 
with an affinity of Kd ≈ 1.6 μM and a maximal BMP-2 surface density of Γmax ≈ 1000 ng/cm2. 
For this analysis, it has to be considered that HS is not a homogeneous polymer: the 
constituent monosaccharides are variably sulfated and/or might exist as different epimers, 
(regions of high sulfation coexisting with regions of low sulfation along individual HS chains). 
These structural features can also vary from one HS source to another.[27, 28] It is therefore 
likely that HS presents a spectrum of binding sites rather than a single type. The affinity 
constant of 1.6 μM should thus be considered as an effective value, resulting from a spectrum 
of binding sites with different affinities.[29] For comparison, an affinity of 20 nM for Hp has 
been previously reported,[12] indicating that a high degree of sulfation might indeed 
substantially enhance the effective binding strength in comparison to the value obtained here. 
At the maximal surface density predicted by the Langmuir isotherm (Γmax = 1000 ng/cm2), we 
calculated that up to 11 BMP-2 dimers would bind to a 12 kDa b-HS chain; in such condition 
~2.1 HS disaccharides are available on average per BMP-2 dimer. A small non-specific 
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binding of BMP-2 to the SAv monolayer has to be considered when high BMP-2 
concentrations are used (Figure S4A). At high concentration it is also possible that several 
BMP-2 molecules interact with each other forming aggregates (Figure S4B). Moreover, 
BMP-2 in solution has been found to have a limited physical stability, with aggregates of 
various sizes forming in a pH-dependent manner.[30] Future studies using shorter 
oligosaccharides (down to 3 disaccharides) would be useful to study the minimal HS/Hp 
disaccharides length able to bind BMP-2.  
The desorption of BMP-2 upon buffer rinsing is well described by the exponential function 
(Figure S3A, red line): 
  (2) 
with an apparent off-rate koff = 6.1 ± 1.9 × 10
-4 s-1. Γir and Γr correspond, respectively, to 
BMP-2 fractions that are irreversibly and reversibly bound to the b-HS film. The fit reveals 
similar values for Γir and Γr , meaning that approximately 50% of BMP-2 is released from the 
b-HS film. The heterogeneous structure of HS chains[28] and the spectrum of binding sites and 
affinities that results from it may well explain the presence of a BMP-2 fraction that binds HS 
reversibly and another fraction that binds HS stably.  
SE was also used to control the surface density of the active biomolecules, a fundamental 
piece of information to perform studies on BMP-mediated cellular responses (Figure 2). To 
this end, the assembly of biomimetic surfaces was followed step by step, as for the QCM-D 
measurements. The areal mass densities obtained from the SE data are reported in Table 1.  
b-HS binds to SAv (Figure 2A and Table 1) and, considering SAv molecular mass of 60 kDa, 
the amount of HS bound on average per available biotin-binding site (assuming that two of 
four sites engage in the immobilization to the surface) is 6  1.6 kDa. This value is below the 
average HS molecular mass employed (12 kDa). As previously discussed[23], this discrepancy 
is likely to be due to the large size distribution of HS in solution, i.e. capture on SAv has 
selected the shorter chains in the initial HS sample.  
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Thanks to the quantification of surface densities afforded by SE, we estimate that, at 96 nM 
concentration, each BMP-2 dimer has approximately 20 kDa of HS, corresponding to roughly 
36 disaccharides, available on average at signal stabilization. 
Noggin, does not bind to SAv (Figure S5A), as expected, but has a HS/Hp binding site[31] and 
indeed readily binds to the native b-HS film, at an areal mass density of ~ 112  0.7 ng/cm2 
when incubated at ~200 nM (Figure S5B). When BMP-2 loaded b-HS film is incubated with 
noggin at the same concentration, noggin binds to the film (Figure 2A and Table 1). The total 
amount of b-HS bound proteins (BMP-2 + noggin) is higher than the amount the individual 
proteins adsorbed on b-HS. This indicates that both proteins can be present in the b-HS film 
simultaneously, however it remains unclear whether b-HS-bound noggin recognizes at the 
same time BMP-2.  
At a concentration of 96 nM, one b-BMP2 binds on average to two SAv molecules (Figure 
2B), which is expected to be due to the larger dimensions of BMP-2 compared to SAv (~8 nm 
vs. ~5 nm). After immobilization of b-BMP-2 on SAv, we added noggin and observed that it 
binds at a ratio of 1 b-BMP2 to 0.7 noggin molecules (Figure 2A). As noggin is known to 
bind BMPs with a 1:1 stoichiometry,[17] this implies that ~30% of immobilized b-BMP2 is 
apparently not recognized by noggin. Plausible explanations are that the noggin binding site 
of some BMP-2 molecules is oriented towards the surface and therefore not accessible, and/or 
that the biotin-PEG-NHS is reacting with Lys 97 and/or Lys 101, thus protecting the binding 
epitope recognised by noggin[7] (Figure 1A). Noggin inhibits BMP signalling by blocking 
BMP binding epitopes for both BMPRI and BMPRII.[17] It is therefore likely that all b-BMP2 
molecules recognized by noggin are also accessible to cell surface receptors. 
To understand how the type of BMP-2 immobilization impacts on BMP-2 and noggin 
biological activity, we next performed functional experiments using BMP-responsive cells. 
Murine C2C12 myoblasts and mesenchymal stem cells from human bone marrow (hMSC) 
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were plated for short periods (30 to 180 minutes) on the biomimetic platforms to compare the 
bioactivity of soluble BMP-2 (sBMP-2), immobilized b-BMP-2 and b-HS/BMP-2. 
We first characterized the signaling response in C2C12 cells, which form myotubes upon 
reaching confluency by switching to low serum condition,[32] but in presence of BMP-2 their 
myogenic differentiation is inhibited resulting in transdifferentiation towards the osteogenic 
lineage.[33] The phosphorylation level of SMAD 1/5 proteins, which are direct downstream 
effectors of the canonical BMP-SMAD signaling pathway, was used as indicator for BMP-2 
bioactivity. We previously demonstrated that the covalent immobilization of BMP-2 on a 
surface via a heterobifunctional chemical linker retained the growth factor’s biological 
activity and triggered BMP-mediated signaling in C2C12 cells.[34] In the present study, we 
investigate the effect of BMP-2 surface presentation via b-HS, which resembles its 
presentation in the ECM, in comparison to its surface immobilization via biotin. In both 
platforms BMP-2 surface concentration was determined to be in the range of 35 to 50 ng/cm2 
(Table 1). As reference, we used sBMP-2 at a concentration of 20 nM.[2] Surfaces presenting 
only b-HS were used as negative control. p-SMAD 1/5 phosphorylation kinetics were 
determined at 30, 90 and 180 minutes after cell plating (Figure 3A and C). While SMAD 1/5 
phosphorylation induced by sBMP-2 decreases during a 3-hour stimulation period, the same 
could not be observed when BMP-2 is bound to b-HS or in the case of b-BMP2 immobilized 
on SAv. In particular, for the latter, SMAD 1/5 phosphorylation peak is delayed at 90 minutes 
and remained stable also for 180 minutes, in line with what has been previously observed for 
covalently immobilized BMP-2.[34] After 180 minutes, the levels of phosphorylated SMAD 
1/5 are significantly higher in cells exposed to BMP-2 bound to b-HS than in presence of 
sBMP-2. Interestingly, for all the measured time points, a significant enhancement of p-
SMAD 1/5 levels is observed when BMP-2 is presented through b-HS in comparison to b-
BMP-2 (Figure 3A). To discard the possibility that b-HS enhances SMAD phosphorylation 
independently of sBMP-2, we used the mutated form of BMP-2 unable to bind HS (EHBMP-
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2) on b-HS platforms. In this setting SMAD 1/5 phosphorylation levels at 180 minutes were 
similar for both sBMP-2 and sEHBMP-2, and in the case of EHBMP-2 they were also not 
increased by the presence of b-HS (Figure S6), suggesting that the enhancement of BMP-2 
bioactivity is due to the specific presentation of BMP-2 by b-HS. It is thus conceivable that b-
HS presents BMP-2 in the correct orientation to the BMP receptor complex. 
Taken together, these results show that both immobilization strategies (b-BMP2 and b-
HS/BMP-2) prolong the biological activity of the growth factor in comparison to its 
presentation to cells when added in the culture media. On b-HS presenting surfaces, the 
retention of BMP-2 might be favored by the cross-linking of the b-HS film (Figure S2). We 
further demonstrate that the presentation via b-HS enhances BMP-mediated signaling in 
C2C12 cells in comparison to its direct immobilization on SAv. To test the role of b-HS as 
co-factor and to better elucidate the nature of the binding between b-HS and BMP-2, the 
affinity of the complex b-HS/BMP-2 to BMP receptors and the functional blocking of HSPGs 
should be addressed in future studies.  
We observed a similar result in the kinetics of SMAD 1/5 phosphorylation in primary hMSCs 
in response to the same immobilization strategy (Figure 3C). Indeed, on b-BMP2, SMAD 1/5 
phosphorylation is prolonged for 180 min, while it decreased over time in presence of sBMP-
2. In contrast to C2C12 cells, the presence of b-HS does not enhance BMP-2 signaling in 
hMSCs in comparison to the presentation of BMP-2 immobilized on SAv, which generates 
also high and sustained levels of p-SMAD 1/5 expression. Furthermore, a short-time 
stimulation of hMSCs on b-HS/BMP-2 and b-BMP2 presenting surfaces is sufficient to 
promote osteogenic differentiation. Cells plated for 90 minutes on the biomimetic platforms in 
the presence of BMP-2, either immobilized or added to the cell media, and then re-plated for 
24 days on untreated tissue culture plates, express alkaline phosphatase (ALP), a marker of 
osteogenic differentiation,[1] without and additional factors (Figure S7). The observed ALP 
expression in cells exposed to surfaces presenting b-HS and BMP-2 is significantly higher 
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than the expression in cells exposed to sBMP-2. We conclude that early events triggered by 
the presentation of BMP-2 via b-HS are sufficient to activate the SMAD1/5 downstream 
signaling, which induces hMSCs differentiation towards the osteogenic lineage. 
To assess whether the presence of b-HS prevents BMP-2 recognition by its antagonist noggin, 
as previously suggested for soluble HS (sHS),[20] we analyze short-term BMP-2 signaling on 
surfaces presenting BMP-2 bound to b-HS or b-BMP2 bound to SAv in the presence of a 
double molar excess of noggin in solution (Figure 3B and D). As comparison, the same molar 
ratio has been used for sBMP-2 and for sBMP-2 bound to sHS. C2C12 and hMSCs responded 
in a comparable manner, demonstrating that noggin, by occupying to BMPRI and BMPRII 
binding epitopes, is able to inhibit the bioactivity of sBMP-2, sBMP-2 bound to sHS and b-
BMP2 grafted on SAv. Surprisingly, when BMP-2 is bound to b-HS, the effect of noggin is 
negligible. To rule out the effect of BMP-2 released from b-HS (Figure S3) we exposed cells 
to an excess of soluble noggin, which we expect to antagonize the biological activity of the 
released BMP-2. We demonstrate that even in presence of an excess of noggin in solution (ref. 
b-HS BMP-2 noggin excess), Smad 1/5 phosphorylation levels remain high. 
We speculate therefore that noggin does not efficiently recognize BMP-2 bound to b-HS, thus 
leaving a sufficient amount of BMP-2 which is bound to b-HS and still accessible to BMPRI 
and BMPRII to activate the SMAD 1/5 pathway. Future studies on the competition between 
b-HS/BMP-2 complex, noggin and BMP receptors might better clarify the impact of HS on 
BMP-2 interaction with noggin and with BMP receptors. Moreover, to consolidate our 
observations, platforms presenting controlled HS sulfation patterns and HS from different 
sources, are in the scope of future studies.  
 
CONCLUSIONS:  
We designed a biomimetic and versatile platform for molecular and cellular studies, which 
presents immobilized BMP-2 alone (b-BMP2) or bound to b-HS grafted via its reducing end 
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to SAv monolayers, similar to BMP-2 presentation by HSPGs in the ECM. By controlling the 
surface density and the stoichiometry of all components, we defined the apparent binding 
affinity between BMP-2 and b-HS and we demonstrated that BMP-2 can cross-link b-HS 
chains likely due to several independent Hp/HS binding sites at the N-terminus. These 
platforms represent therefore a versatile and tuneable biomimetic tool able to be exploited as 
active substrates for C2C12 and hMSCs stimulation towards osteogenic differentiation. We 
show that (i) surface immobilization of BMP-2 prolongs the p-SMAD 1/5 signalling 
activation with respect to the soluble BMP-2, (ii) the specific presentation via b-HS enhances 
the p-SMAD 1/5 levels on C2C12 cells and prevents the antagonistic effect of noggin on both 
C2C12 and hMSCs. Our study, therefore, highlights the potential importance of ECM HSPGs 
as regulators of BMP-2 activity, giving new insights into the molecular basis of ECM-BMP 
interactions and opening avenues for novel strategies to design biomimetic materials 
functionalized with BMP-2 in regenerative medicine. 
 
 
 
Experimental Section  
Further information on the experimental materials and methods are available in the supporting 
information. 
Supporting Information  
Supporting Information is available from the Wiley Online Library. 
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Figure 1. A: BMP-2 homodimer structure (PDB: 3BMP). B: Schematic representation of the 
biomimetic platforms. C-D: QCM-D characterization. Frequency shifts: Δf - blue lines with 
square symbols; dissipation shifts: ΔD - red lines. Start and duration of incubation steps are 
indicated by arrows; during all other times, the surface was exposed to working buffer.  
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Figure 2. Surface functionalization is followed in situ by SE on a gold-supported OEG 
monolayer. Sample concentrations are: 83 nM SAv, 0.8 μM b-HS, 96 nM BMP-2, b-BMP2 and 
200 nM noggin. Each incubation step started at 0 min; start of rinsing in working buffer is 
indicated by arrows. 
 
 
Figure 3. C2C12 cells (A, B) and hMSCs (C, D) plated on functionalized surfaces and lysed, 
at different time points (A, C) or after 90 minutes on substrates incubated with or without 
noggin (B, D,). p-SMAD 1/5 expression analyzed by Western Blot.  
 
 
 
Table 1. Data was extracted from SE measurements at signal stabilization (Figure 2). Mean 
values and standard errors from the mean were derived from 3 independent measurements. On 
the basis of these numbers we quantify the number of molecules grafted per unit surface area 
and the stoichiometry of binding. 
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Compound Areal 
mass 
density 
(ng/cm
2
) 
SAv 204.3±9.9 
+ b-BMP2 44.2±4.6 
+ noggin 57.6±2.1 
b-HS 40.7±3.5 
+ BMP-2 (eq)  53.2±4.6 
+ BMP-2 (rins) 35.3±2.7  
+ Noggin 112±4.1 
 
(eq) value close to equilibrium during BMP-2 injection; (rins) value after BMP-2 rinsing with 
working buffer until plateau was reached. 
 
 
Table of contents: Biomimetic platforms reproducing in vitro the BMP-2 presentation 
via extracellular matrix (ECM)-associated heparan sulfate proteoglycans (HSPGs). A 
bottom-up approach is used to functionalize biomimetic surfaces and to investigate the role of 
ECM-associated HS on the biological activity of BMP-2.  
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